Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.59 | N/A | -16.65% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.59 | N/A | -16.65% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concern over current performance but highlighted initiatives aimed at addressing these issues.
Management acknowledged the challenges faced in the quarter.
They emphasized ongoing efforts to improve operational efficiency.
The earnings report indicates that ACADIA Pharmaceuticals is struggling with its financial performance, particularly with a larger-than-expected loss per share. The stock reacted negatively, dropping 1.62%, reflecting investor concerns about the company's current trajectory and lack of guidance for future performance. Without clear direction from management, uncertainty may linger among investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WESTERN DIGITAL CORP
Apr 29, 2019